Lynch Syndrome and Breast Cancer Risk: Weighing the Data

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2020 Sep 14

PMID 32923871

Citations 4

Authors

Wendy Kohlmann

Affiliations

Soon will be listed here.

Citing Articles

Hormone Receptor-Positive Breast Cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the MLH1 Variant 1835del3.

Kaplan H, Whiteaker J, Nelson B, Ivey R, Lorentzen T, Voytovich U J Natl Compr Canc Netw. 2023; 21(11):1110-1116.

PMID: 37643636 PMC: 11051703. DOI: 10.6004/jnccn.2023.7035.

Contralateral lymph node metastasis in recurrent ipsilateral breast cancer with Lynch syndrome: a locoregional event.

Zwimpfer T, Schwab F, Steffens D, Kaul F, Schmidt N, Geiger J World J Surg Oncol. 2023; 21(1):40.

PMID: 36755294 PMC: 9909893. DOI: 10.1186/s12957-023-02918-w.

Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancer.

Megid T, Barros-Filho M, Pisani J, Achatz M Front Oncol. 2022; 12:873395.

PMID: 36003761 PMC: 9393394. DOI: 10.3389/fonc.2022.873395.

Significance of rare variants in genes involved in the pathogenesis of Lynch syndrome.

Liccardo R, Lambiase M, Nolano A, De Rosa M, Izzo P, Duraturo F Int J Mol Med. 2022; 49(6).

PMID: 35475445 PMC: 9083887. DOI: 10.3892/ijmm.2022.5137.

References

Ten Broeke S, van der Klift H, Tops C, Aretz S, Bernstein I, Buchanan D . Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018; 36(29):2961-2968. PMC: 6349460. DOI: 10.1200/JCO.2018.78.4777. View

Wang X, Brzosowicz J, Park J . Response to Roberts et al. 2018: cohort ascertainment and methods of analysis impact the association between cancer and genetic predisposition - the tale of breast cancer risk and Lynch syndrome genes MSH6/PMS2. Genet Med. 2019; 21(9):2156-2157. DOI: 10.1038/s41436-019-0471-8. View

Dominguez-Valentin M, Sampson J, Seppala T, Ten Broeke S, Plazzer J, Nakken S . Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2019; 22(1):15-25. PMC: 7371626. DOI: 10.1038/s41436-019-0596-9. View

Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupfer S . No Evidence of Increased Risk of Breast Cancer in Women With Lynch Syndrome Identified by Multigene Panel Testing. JCO Precis Oncol. 2022; 4:51-60. DOI: 10.1200/PO.19.00271. View

Win A, Lindor N, Jenkins M . Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res. 2013; 15(2):R27. PMC: 3672741. DOI: 10.1186/bcr3405. View

Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg L, Nilbert M . Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer. 2017; 117(11):1702-1710. PMC: 5729445. DOI: 10.1038/bjc.2017.348. View

Win A, Jenkins M, Dowty J, Antoniou A, Lee A, Giles G . Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2016; 26(3):404-412. PMC: 5336409. DOI: 10.1158/1055-9965.EPI-16-0693. View

Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans D . Cancer risk and survival in carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2017; 67(7):1306-1316. PMC: 6031262. DOI: 10.1136/gutjnl-2017-314057. View

Gupta S, Provenzale D, Llor X, Halverson A, Grady W, Chung D . NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019; 17(9):1032-1041. DOI: 10.6004/jnccn.2019.0044. View

10.

Evans D, WOODWARD E, Lalloo F, Moller P, Sampson J, Burn J . Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genet Med. 2019; 21(8):1878-1879. DOI: 10.1038/s41436-018-0401-1. View

11.

Roberts M, Jackson S, Susswein L, Zeinomar N, Ma X, Marshall M . MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med. 2018; 20(10):1167-1174. PMC: 6051923. DOI: 10.1038/gim.2017.254. View

12.

Slavin T, Maxwell K, Lilyquist J, Vijai J, Neuhausen S, Hart S . The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. 2017; 3:22. PMC: 5466608. DOI: 10.1038/s41523-017-0024-8. View

13.

Espenschied C, LaDuca H, Li S, McFarland R, Gau C, Hampel H . Multigene Panel Testing Provides a New Perspective on Lynch Syndrome. J Clin Oncol. 2017; 35(22):2568-2575. PMC: 7186580. DOI: 10.1200/JCO.2016.71.9260. View

14.

Ten Broeke S, Suerink M, Nielsen M . Response to Roberts et al. 2018: is breast cancer truly caused by MSH6 and PMS2 variants or is it simply due to a high prevalence of these variants in the population?. Genet Med. 2018; 21(1):256-257. DOI: 10.1038/s41436-018-0029-1. View